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Background: Budesonide at 800 mg/d is generally suggested for treatment of nonasthmatic
eosinophilic bronchitis (NAEB). In asthma, adjunctive therapy with montelukast has been
shown to confer addictive anti-inflammatory effects to inhaled corticosteroid (ICS). However,
whether such effects could be extrapolated to NAEB is not known.
Objectives: To study the efficacy and tolerability of add-on therapy with montelukast as
compared to double-dose ICS in suppressing airway eosinophilia and decreasing cough severity
in NAEB.
Methods: In a randomized controlled trial, 26 nonsmoking, steroid-naı¨ve NAEB patients pre-
senting with chronic cough were treated with 800 mg/d budesonide or 400 mg/d budesonide
plus montelukast 10 mg/d for 4 weeks. Cough visual analogue scale (CVAS) and eosinophil
differential ratio in induced sputum (Eos) were monitored at baseline, Week 1, 2 and 4.
Adverse events during treatment were recorded.
Results: The two groups were comparable in age, gender distribution, cough duration, FEV1%
predicted, FEV1/FEV ratio, baseline CVAS and geometric mean of Eos. Both regimens signifi-
cantly reduced Eos and CVAS throughout the treatment course, with abrogation of sputum
eosinophilia at end of therapy. There was no significant difference between the two groups
in reduction of Eos and CVAS at all time points. Both regimens were well tolerated.e of Chest Physicians; AR, allergic rhinitis; BPT, bronchial provocation test; BUD, budesonide tur-
budesonide combination therapy; CVA, cough-variant asthma; CVAS, cough visual analogue scale; cys-
nophil differential count in induced sputum; GERD, gastroesophageal reflux disease; FEV1, forced
vital capacity; GM, geometric mean; ICS, inhaled corticosteroids; LFT, lung function test; LTRA,
T, montelukast; NAEB, nonasthmatic eosinophilic bronchitis; PC20, provocative concentration of
FEV1.
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1370 C. Cai et al.Conclusions: This preliminary study demonstrated that add-on montelukast might be an effec-
tive and well tolerated alternative to the generally suggested dose of ICS in treating steroid-
naive NAEB, with suppression of eosinophilic inflammation, reduction of cough severity and
sparing of ICS doses. (NCT01121016).
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Defined as airway eosinophilia without evidence of airway
hyperresponsiveness and variable airflow obstruction,
nonasthmatic eosinophilic bronchitis (NAEB) is one of the
most common causes of chronic cough, accounting for 10%e
30% of patients seen in respiratory specialist clinic.1,2 At
present, inhaled corticosteroids (ICS) is the first-line phar-
macotherapy recommended by the 2006 American College
of Chest Physicians (ACCP) evidence-based clinical practice
guidelines on chronic cough due to NAEB.1 Although the
variety of ICS, its optimal dose and course has not been
defined by the guidelines,1 inhaled budesonide (BUD) at
800 mg/d or the equivalent dose of fluticasone is generally
suggested3 and used to treat NAEB.2,4,5 Occasionally, oral
corticosteroids are required when eosionophilic inflamma-
tion persists or progresses despite ICS therapy.1,6,7 In
addition, antileukotrienes and antihistamines have been
suggested as potential therapeutic agents for treatment of
NAEB.1,8 However, to the best of our knowledge, there has
been no public report on such trials in English literature.
Cysteinyl leukotrienes (cys-LTs) play important role in
the pathogenesis of allergic inflammation, with compelling
evidence of upregulation of cys-LTs in both asthma and
NAEB.9e16 Though the anti-inflammatory effects of mon-
telukast (MONT) are generally believed to be milder as
compared to ICS in GINA guidelines on asthma,17 for most
studies on add-on MONT in asthma, MONT conferred
addictive anti-inflammatory effects to ICS, with better
symptom control, improvement of lung function, protection
against airway narrowing as compared to double-dose
ICS.11e13 In addition, many in vivo and in vitro studies
support that the proinflammatory pathway of cys-LTs are
independent of those suppressed by corticosteroids.9,10
Similar to previous studies,14,15 our previous work also
detected elevation of cys-LTs in induced sputum in patients
with NAEB,16 suggesting involvement of cys-LTs in the
pathogenesis of NAEB. Accordingly, we hypothesized that
MONT as a potent and selective cys-LTs receptor antagonist
(LTRA), might confer addictive anti-inflammatory effects to
ICS in NAEB, and conducted a 4-week, single-centre, open-
label, randomized controlled trial to study the efficacy and
tolerability of BUD-MONT combination therapy as compared
to double-dose BUD in patients with steroid-naı¨ve NAEB.Figure 1 Patient flow. EOT Z end of therapy.Methods
Subjects
Of 764 patients presented with chronic cough (defined as
cough lasting over 8 weeks without overt clinicoradiologicalevidence of lung disease18) seen by Drs Cai, Tang, NS Zhong
and SQ Zhong at the respiratory specialist clinic of the First
Affiliated Hospital of Guangzhou Medical University
between May 2010 and February 2011, 65 were diagnosed
with steroid-naive NAEB according to the 2006 ACCP
guidelines.1 Following the anatomic diagnostic protocol
recommended by the 2006 ACCP cough guidelines,18 after
careful exclusion of active cigarette smoking, exposure to
commonly-reported occupational allergens or sensitizers as
possible causes of NAEB,19 co-morbidity with allergic
rhinitis (AR) and/or gastroesophageal reflux disease
(GERD),20,21 only 26 patients (40.0%) willing to participate
in the study were successfully recruited (Fig. 1). Patients
with the following conditions were also excluded: history of
taking antileukotrienes, angiotensin converting enzyme
inhibitors or bacterial/viral respiratory infections within 14
days prior to enrollment, pregnant or lactating women,
known allergy to MONT or BUD, inability to use ICS correctly
despite repeated instructions, presence of malignancy
undergoing active therapy, life-threatening co-morbidities
such as severe heart, lung, liver or kidney diseases. All the
participants gave written informed consents. The study
protocol was approved by the Ethics Committee of the First
Affiliated Hospital of Guangzhou Medical University.
Subjects were then randomized into the BUD Group (13
patients, BUD 400 mg twice daily, 4 weeks) or BUD-MONT
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daily, 4 weeks) (Fig. 1). Sputum induction and CVAS scoring
were conducted at baseline, Week 1, 2 and 4. Spirometry
and bronchial provocation test were performed at baseline
and Week 4 (end of therapy). Patients were encouraged to
record any adverse event and report these events to their
treating physicians. Evaluation of adverse events and veri-
fication of compliance with treatment (tablet counting and
assessment of turbuhaler use) were done at each visit
(scheduled at Week 1, 2 and 4). During the study period,
systemic corticosteroids, antihistamines, beta 2-agonist,
antitussives or protussives (expectorants) and angiotensin
converting enzyme inhibitors were prohibited.
Singulair (Merck & Co., Hangzhou, China) tablets con-
taining 10 mg MONT sodium per tablet and Pulmicort
Turbuhaler (AstraZeneca, Lund, Sweden) with 100 mg BUD
power delivered per puff were used in this study.
Our co-primary endpoints were CVAS and Eos at baseline
and during treatment, secondary endpoint was adverse
events during treatment.
Measurements
Similar to our previous study, spirometry was performed
using a dry spirometer (Masterscreen IOS, Jaeger, Wu¨rz-
burg, Germany); airway hyperresponsiveness was deter-
mined using histamine challenge (tidal breathing) with PC20
histamine >7.8 mg/mL interpreted as negative; atopy was
determined by skin prick test for 12 common aeroallergens
including house dust mites, cockroaches, animal furs, mold
and grass pollens (ALK-Abello´, Hørsholm, Denmark); sputum
induction was performed by inhalation of nebulized 4.5%
hypertonic saline with 400 nonsquamous cells counted for
every sputum specimen.19 The technician responsible for
sputum induction and processing for total and differential
cell counts was blinded to the grouping of the subjects.
Spirometry and bronchial provocation test with histamine
challenge generally preceded sputum induction. For each
subject, the tests were repeated in the same sequence and
conducted at the same time of the day.4,19 Cough severity
was assessed using CVAS, a 100 mm horizontal visual
analogue scale with 0 being no cough and 100 equalling to
the worst cough ever.4,22Table 1 Patients’ baseline demographic, clinical and laborator
BUD (n Z 13)
Age(range), yr 36.2  12.4(22
Gender (F:M) 9:4
Cough duration, Median(range),mo 8(4e32)
Atopy 53.8%
FEV1% predicted 93.1%  4.37
FEV1/FVC 79.2%  3.77
AHR Negative
Eos(range) 3.5%e70.6%
GM(SEM) 25.37%  5.59
CVAS(range), mm 70.4  8.28(60
yrZ year, moZmonth, AHRZ airway hyperresponsiveness, CVASZ c
induced sputum, GM Z geometric mean.Statistical analysis
Normally distributed data were expressed as mean (SEM),
log normally distributed data (Eos) was described as
geometric mean (SEM) and non-normally distributed data
(cough duration) were described as median. Numeric vari-
ables were compared with One-way ANOVA or Man-
neWhitney U test (cough duration) whereas categorical
data was examined with Pearson chi-square test. Pearson’s
correlation test was used to assess correlation between
CVAS and Eos (log transformed). Changes of FEV1% pre-
dicted and FEV1/FVC at baseline and end of therapy were
analyzed using paired Student’s t test. All hypothesis tests
were two-sided, and p < 0.05 was defined as significant.
SPSS 13.0 (SPSS Inc., Chicago, IL, USA) was used for statis-
tical analysis.
Results
Demographic, clinical and laboratory
characteristics of subjects with NAEB
(Fig. 1 and Table 1)
Steroid-naive NAEB accounted for 8.9% of patients pre-
sented with chronic cough in this specialist clinic. As
demonstrated in Fig. 1, of 65 patients with steroid-naive
NAEB, 21.5% had AR as co-morbidity, 9.2% had GERD, and
12.3% had both AR and GERD.
As shown in Table 1, the two groups were comparable in
age, gender distribution, cough duration, atopy status,
baseline FEV1% predicted, FEV1/FVC ratio, Eos (log trans-
formed) and CVAS (p > 0.05 for all variables). All subjects
tested negative for airway hyperresponsiveness with PC20
histamine>7.8 mg/mL.
Changes of Eos during treatment (Fig. 2)
As demonstrated in Fig. 2, for subjects in BUD or BUD-
MONT, compared with baseline values (25.37%  5.59,
95CI 13.19e37.51 vs 21.08%  5.54, 95CI 8.99e33.16), both
treatments substantially reduced Eos since Week 1
(p < 0.0001 at each treatment course), with reduction ofy data.
BUD-MONT (n Z 13) p
e65) 38.6  12.5(19e55) 0.643
8:5 0.680
9(5e26) 0.836
46.2% 0.695
91.3%  4.63 0.309
80.6%  3.12 0.310
Negative 1.00
3.2%e65.1%
21.08%  5.54 0.487
e85) 73.5  7.94(60e80) 0.288
ough visual analogue score, EosZ eosinophil differential count in
Figure 2 Changes of Eosinophil differential count in induced
sputum (Eos) during treatment.
1372 C. Cai et al.Eos being in parallel with treatment course, and most
profound between baseline and Week 1. At end of therapy,
Eos in all subjects was reduced below 3% (BUD vs BUD-
MONT, 1.48%  0.16, 95% CI 1.13e1.84 vs 1.44  0.12,
95%CI 1.19e1.69). There was no significant difference
between the two groups for reduction of Eos at each
treatment course (p > 0.05).Changes of CVAS during treatment (Fig. 3)
As demonstrated in Fig. 3, for subjects in BUD or BUD-
MONT, compared with baseline values (70.4  2.30 mm,
95% CI 65.38e75.40 vs 73.85  2.20 mm, 95% CI
69.04e79.85), both treatments substantially reduced CVAS
since Week 1 (mean difference 9.61 mm, 95% CI
3.57e15.67, pZ 0.002 vs mean difference 14.2 mm, 95% CI
7.60e20.87, p < 0.0001), with reduction of CVAS being in
parallel with treatment course, and most profound in the
last two weeks of treatment. In addition, for both groups,
the decrease of CVAS was statistically significant between
baseline and 1 week of treatment, 1 week and 2 week of
treatment, 2 week and 4 week of treatment (p < 0.01) at
each time interval. There was no significant difference
between the two groups for reduction of CVAS at each
treatment course.Figure 3 Changes of cough visual analogue scale (CVAS)
during treatment.Association between CVAS and Eos at baseline and
during treatment
Similar to the observation by Berry et al,6 though the
reduction of CVAS and Eos was in parallel with the treat-
ment course, there was no significant correlation between
CVAS and Eos at baseline and at each time point during
treatment when analyzed by Pearson’s correlation test.
Spirometric parameters at baseline and end of
therapy
For subjects in BUD or BUD-MONT, there was no significant
change in FEV1 % predicted (mean difference 0.42%, 95%
CI 0.35e0.87, p Z 0.67 vs mean difference 0.31%, 95%
CI 1.61e0.99, p Z 0.62) and FEV1/FVC (mean difference
1.17%,95%CI 0.22e2.36, p Z 0.054 vs mean difference
1.55%, 95%CI 1.12e4.23, p Z 0.23) at baseline and end
of therapy.
All subjects tested negative for airway hyper-
responsiveness with PC20 histamine>7.8 mg/mL at end of
therapy. All subjects completed the preliminary study. Both
regimens were well tolerated without significant adverse
events reported during treatment.Discussion
We describe for the first time that add-on MONT is similar to
double-dose BUD (800 mg/d), the generally suggested
regimen to treat NAEB, in suppressing eosinophilic airway
inflammation and reducing cough severity in patients with
steroid-naive NAEB, suggesting a possible adjunctive anti-
inflammatory role of LTRAs in NAEB similar to such effects
in asthma.
To accurately evaluate the anti-inflammatory effects of
both regimens on cough symptom in these subjects pre-
sented with chronic cough, stringent eligibility criteria
were applied to exclude medical conditions other than
NAEB as causes of chronic cough. As a consequence, only
40% patients were successfully recruited, with 50.7%
excluded for having co-morbidities that might hinder the
interpretation of the impact of inflammation suppression
on cough severity. In sharp contrast to the abundance of
subjects with asthma,11e13 this also highlighted the diffi-
culty in recruiting sufficient number of subjects with NAEB
in clinical practice.2,4e7,19,23 This limitation has many
ramifications: possible reduction of the statistical power,
difficulty in calculating optimal sample size for non-
inferiority study, and impairment in sub-division of
subjects especially when dose-response to different treat-
ment regimens is the primary outcome measure.
Before we can elaborate on the clinical effects of the
two regimens, it is utmost important to clarify a critical
point raised by the reviewers: whether 400 mg/d BUD
monotherapy is adequate to suppress eosinophilic inflam-
mation and reduce cough in NAEB, as there is an overt
defect with the study design: lack of a control group or
a run-in period to assess the clinical effects of 400 mg/d
BUD. Though we cannot rule out such a possibility,
however, the following arguments should be taken into
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the optimal dose of ICS is not defined in the 2006 ACCP
clinical practice guidelines on chronic cough due to NAEB1;
secondly, later on, as put by the Gonlugurs in their
review,3 800 mg/d BUD or equivalent dose of fluticasone is
generally suggested and widely used to treat NAEB, with
suppression of airway eosinophilia and reduction of cough
symptom.2e5 Occasionally (2 in 7 with 800 mg/d beclome-
thasone; 2 in 32 with 200e400 mg/d BUD), oral cortico-
steroids are required when low to medium dose ICS
failed.1,6,7 Though dose response to ICS is difficult to
establish in NAEB, based upon the above-mentioned clin-
ical data (800 mg/d instead of 400 mg/d is the commonly
used dose of BUD for steroid-naive NAEB, and occasionally
ICS at such dose could not suppress eosinophilic inflam-
mation and prevent disease progression in NAEB), it is
reasonable to assume that 400 mg/d BUD monotherapy can
not be adequate to suppress eosinophilic inflammation in
all patients with steroid-naive NAEB. Finally, even for
patients responding to 400 mg/d BUD, with the optimal
dose of ICS undetermined in NAEB, the complementary
anti-inflammatory role of LTRAs still could not be denied,
as one can argue that what about 200 mg/d BUD plus MONT,
and so on.
In general, with difficulty to recruit enough subjects to
meet the stringent eligibility criteria, and with BUD at
800 mg/d as the generally accepted regimen for treatment
of NAEB,2e5 for a clinical trial aimed to investigate the non-
inferiority of add-on MONT to double-dose ICS, it might be
understandable and reasonable for we to select BUD at
800 mg/d as the control group, though the inclusion of
another control group using 400 mg/d BUD alone could make
our observations more convincing.
Sputum eosinophlia as index of eosinophlic airway
inflammation, is one of the defining features of NAEB.1e8
Consistent with previous findings,2,4,23 significant reduc-
tion of Eos was evident on Week 1 following initiation of
ICS treatment in both groups, with sputum eosinophilia
being absolutely abrogated on Week 4 (Fig. 2). At different
time points during treatment, the reduction of sputum
eosinophilia achieved by add-on MONT was similar to that
achieved by double-dose BUD. In both groups, the
suppression of airway eosinophilia was most apparent
following 1 week of treatment, with sustained anti-
inflammatory effects throughout the 4-week treatment
course.
This complementary anti-inflammatory effect conferred
by MONT is similar to the results demonstrated in most
studies investigating adjunctive therapy with anti-
leukotrienes in asthma.11e13,17 Since airway eosinophilia
and significant elevation of cys-LTs in airway milieu are
evident in both NAEB and asthma,1,9,10,14e16 the suppres-
sion of eosinophilic inflammation achieved by MONT might
act through similar mechanisms in the two eosinophilic
airway diseases.
The successful suppression of eosinophilic airway
inflammation by add-on therapy with MONT, may point to
novel therapeutic target for NAEB, with potential to avert
side effects associated with systemic corticosteroids and to
spare the doses of ICS required to maintain control of
eosinophilic inflammation and cough symptom. This might
be especially meaningful for patients intolerant of ICS, orunresponsive to ICS which necessitated oral corticosteroid
therapy.1,6,7
In these patients presenting with isolated, irritating and
unproductive chronic cough, both regimens substantially
decreased CVAS, the subjective measurement of cough
severity and response to therapy (Fig. 3). In both groups,
the antitussive effects were evident since Week 1, sus-
tained throughout the treatment period, and most
apparent in the last two weeks. Add-on MONTwas similar to
double-dose BUD in suppressing cough at all time points.
This reduction of cough severity was consistent with
previous findings with ICS in NAEB,4,5 whereas the authors
demonstrated for the first time that add-on therapy with
MONT conferred complementary and similar antitussive
effects to double-dose ICS.
The antitussive effect of MONT demonstrated in NAEB
might be similar to the reduction of cough achieved by
LTRAs in cough-variant asthma (CVA),24e26 as CVA and NAEB
share many clinical and immunopathological features with
cough as predominant symptom.27,28 In patients with CVA,
LTRAs such as MONT or zafirlukast substantially improved
objective and subjective measures of cough severity and
suppressed the heightened cough reflex.24e26 In addition, in
patients with CVA,treatment with zafirlukast was shown to
suppress chronic cough unresponsive to prolonged ICS
therapy,24 suggesting that similar to its anti-inflammatory
effects, the antitussive effect of LTRA may be indepen-
dent of the corticosteroid pathway.
Brightling et al reported that eosinophilic airway
inflammation was causally associated enhanced cough
reflex sensitivity in NAEB.4 In this study the improvement of
cough seemed to parallel with the reduction of airway
eosinophilia during therapy. However, similar to the find-
ings by Berry et al,6 no significant correlation was found
between CVAS and Eos at baseline and during therapy. This
is consistent with the nature of airway inflammation in
NAEB, as airway eosinophilia and epithelial infiltration of
activated mast cells are two important histological features
of NAEB.1,3,8,27,28 In this case, airway eosinophilia seems to
be just one of the many contributing factors causing
chronic cough in NAEB.
CVAS, as a valid tool to measure cough severity and
monitor clinical efficacy,22 has been being used in study on
NAEB.4 However, as a subjective measurement, it has
inherent limitations to accurately and objectively reflect
changes in cough severity and clinical response to antitus-
sive therapy. The dissociation between CVAS and Eos
further demonstrated the complex relationship between
airway inflammation and the clinical expression of NAEB.
At end of therapy (4 weeks), all the 26 subjects
demonstrated significant reduction in airway eosinophilia
and cough symptom. There was not any significant adverse
reaction reported by the subjects, with both regimens
being well tolerated. The good compliance profile might
result from the satisfactory therapeutic effects achieved by
both regimens as well as be related to the short study
period and small sample size. The safety profile of MONT
demonstrated in this study is in accordance with those
observed in large-sample studies (adverse reactions repor-
ted in 14 out of 6158 adult patients29) or systemic
reviews.30,31 Careful and repeated instructions on correct
use of ICS, the short study period, small sample size, low to
1374 C. Cai et al.medium-dose BUD used (for example, incidence of oral
candidiasis is less than 3% in asthmatics receiving BUD
800 mg/d32), health condition of the subjects all might
contribute to the absence of significant side effects with
ICS in this study.32
In addition to the lack of a control group or run-in period
to evaluate the clinical effects of 400 mg/d BUD mono-
therapy in NAEB, there are several other limitations with
this preliminary study: Firstly, we acknowledge the limita-
tion associated with the open-label protocol. Possible
observer bias in the assessment of cough severity could be
prevented with the double-blind design providing placebo
to MONT. Secondly, similar to previous studies on
NAEB,2,4e7,14e16,19,23 this study is also limited by its relative
small sample size, which might decrease its statistical
power, have hindered the sub-division of subjects and the
assessment of non-inferiority between the two regimens.
Though, at present, this study with 26 subjects is second
only to Berry and colleagues’ with 32 subjects as for sample
size,2,4e7,14e16,19,23 and it has long been recognized that it
is not easy to recruit large number of patients with NAEB in
one single institution,1,8 multi-centre cooperation may
provide enough patients.
Conclusion
In this pilot study, we found that add-on MONT could ach-
ieve similar anti-inflammatory and antitussive effects to
double-dose ICS (800 mg/d BUD) in steroid-naive NAEB,
pointing to LTRAs as new therapeutic target in the treat-
ment of NAEB, highlighting the involvement of cys-LTs in
the pathogenesis of NAEB. Multi-centre randomized
placebo-controlled trial with inclusion of another control
group to clarify the clinical effect of 400 mg/d BUD mono-
therapy is warranted to confirm the adjunctive role of
LTRAs in treating NAEB.
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